John Fung to Graft Rejection
This is a "connection" page, showing publications John Fung has written about Graft Rejection.
Connection Strength
8.119
-
Limitations of current liver transplant immunosuppressive regimens: renal considerations. Hepatobiliary Pancreat Dis Int. 2017 Feb; 16(1):27-32.
Score: 0.386
-
Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. Transplantation. 2017 Feb; 101(2):341-349.
Score: 0.386
-
Stromal cell-based immunotherapy in transplantation. Immunotherapy. 2011 Dec; 3(12):1471-85.
Score: 0.270
-
Future prospects in immunosuppression for liver transplantation. Liver Transpl. 2011 Nov; 17 Suppl 3:S54-9.
Score: 0.268
-
Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl. 2011 Nov; 17 Suppl 3:S1-9.
Score: 0.268
-
Use of tissue plasminogen activator in liver transplantation from donation after cardiac death donors. Am J Transplant. 2010 Dec; 10(12):2665-72.
Score: 0.252
-
Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant. 2010 Sep-Oct; 24(5):701-8.
Score: 0.247
-
Predicting immunosuppressant dosing in the early postoperative period with noninvasive indocyanine green elimination following orthotopic liver transplantation. Liver Transpl. 2008 Jan; 14(1):46-52.
Score: 0.206
-
Rapamycin: friend, foe, or misunderstood? Liver Transpl. 2003 May; 9(5):469-72.
Score: 0.149
-
Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation. 2002 Nov 15; 74(9):1290-6.
Score: 0.144
-
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl. 2001 Jul; 7(7):623-30.
Score: 0.131
-
Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. Transplant Proc. 2001 Feb-Mar; 33(1-2):1342-4.
Score: 0.127
-
Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. Liver Transpl Surg. 1999 Sep; 5(5):421-8.
Score: 0.115
-
Preservation injury and acute rejection of rat intestinal grafts: protection afforded by pyruvate. J Gastrointest Surg. 1999 Sep-Oct; 3(5):549-54.
Score: 0.115
-
Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis. 1998 Jun; 31(6 Suppl 1):S7-14.
Score: 0.106
-
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
Score: 0.105
-
Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients. Am J Transplant. 2018 10; 18(10):2544-2558.
Score: 0.105
-
C-C Chemokine Receptor Type 2-Dependent Migration of Myeloid-Derived Suppressor Cells in Protection of Islet Transplants. Transplantation. 2017 08; 101(8):1793-1800.
Score: 0.100
-
Interleukin-2 and interleukin-12 mediate distinct effector mechanisms of liver allograft rejection. Liver Transpl Surg. 1997 Mar; 3(2):118-29.
Score: 0.097
-
2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016 10; 16(10):2816-2835.
Score: 0.093
-
Impact of De Novo and Preexisting Inflammatory Bowel Disease on the Outcome of Orthotopic Liver Transplantation. Inflamm Bowel Dis. 2016 07; 22(7):1670-8.
Score: 0.093
-
Impact of donor MHC class I or class II antigen deficiency on first- and second-set rejection of mouse heart or liver allografts. Immunology. 1996 May; 88(1):124-9.
Score: 0.092
-
Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation. 2015 Jul; 99(7):1455-62.
Score: 0.086
-
Presensitization by skin grafting from major histocompatibility complex class I or major histocompatibility complex class II deficient mice identifies class I antigens as inducers of allosensitization. Immunology. 1995 May; 85(1):82-7.
Score: 0.085
-
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation. 1994 Mar 27; 57(6):860-5.
Score: 0.079
-
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014 Feb; 14(2):356-66.
Score: 0.078
-
Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway. Transplantation. 2013 Jul 15; 96(1):17-24.
Score: 0.075
-
State of immunosuppressive agents in organ transplantation. Transplant Proc. 1992 Dec; 24(6):2372-4.
Score: 0.072
-
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012 Jun; 18(6):716-26.
Score: 0.070
-
Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis. 1992 Feb; 12(1):51-9.
Score: 0.068
-
The effect of thymus transplantation on allograft rejection in thymectomized bone marrow chimeras. Transplant Proc. 1990 Dec; 22(6):2536-8.
Score: 0.063
-
A critical role of TRAIL expressed on cotransplanted hepatic stellate cells in prevention of islet allograft rejection. Microsurgery. 2010 May; 30(4):332-7.
Score: 0.060
-
Liver allograft rejection: an overview of morphologic findings. Am J Surg Pathol. 1990; 14 Suppl 1:49-63.
Score: 0.059
-
Near-total human face transplantation for a severely disfigured patient in the USA. Lancet. 2009 Jul 18; 374(9685):203-9.
Score: 0.057
-
Impact of Orthoclone OKT3 on liver transplantation. Transplant Proc. 1987 Apr; 19(2 Suppl 1):37-44.
Score: 0.049
-
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron. 1987; 46 Suppl 1:19-33.
Score: 0.048
-
Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation. 2006 Dec 27; 82(12):1621-4.
Score: 0.048
-
Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006 Aug; 44(2):489-501.
Score: 0.047
-
Preservation solutions in liver transplantation: what are the options? Liver Transpl. 2006 Feb; 12(2):196-8.
Score: 0.045
-
A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006 Jan 12; 354(2):141-50.
Score: 0.045
-
Functional studies of in vivo committed lymphocytes propagated from organ transplants. Prog Clin Biol Res. 1986; 211:59-73.
Score: 0.045
-
Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005 Nov; 11(11):1425-30.
Score: 0.044
-
Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem. Liver Transpl. 2005 Jun; 11(6):679-83.
Score: 0.043
-
Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005 Mar; 37(2):923-6.
Score: 0.042
-
Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol. 2005 Jan; 45(1):34-41.
Score: 0.042
-
Liver transplantation in patients with HIV infection. Liver Transpl. 2004 Oct; 10(10 Suppl 2):S39-53.
Score: 0.041
-
Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol. 2004 May; 28(5):658-69.
Score: 0.040
-
Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. Transpl Int. 2003 Dec; 16(12):849-56.
Score: 0.038
-
Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation. Exp Clin Transplant. 2003 Jun; 1(1):48-55.
Score: 0.037
-
The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Transplantation. 2003 Apr 15; 75(7):1020-5.
Score: 0.037
-
Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report. Ther Drug Monit. 2003 Feb; 25(1):117-9.
Score: 0.037
-
Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2002 Sep; 8(9):838-40.
Score: 0.036
-
Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. Transplant Proc. 2002 Aug; 34(5):1968-9.
Score: 0.035
-
A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl. 2002 Jan; 8(1):40-6.
Score: 0.034
-
Intestinal transplantation: a coming of age. Adv Surg. 2002; 36:65-101.
Score: 0.034
-
A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation. 2001 Sep 27; 72(6):1091-7.
Score: 0.033
-
Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation. 2001 Sep 15; 72(5):851-5.
Score: 0.033
-
Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial. Transplantation. 2022 05 01; 106(5):997-1003.
Score: 0.033
-
An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitis. Am J Transplant. 2001 May; 1(1):47-50.
Score: 0.032
-
Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol. 2001 Apr; 158(4):1379-90.
Score: 0.032
-
Role of MHC class I and CD8(+) T cells in the pathogenesis of chronic rejection. Transplant Proc. 2001 Feb-Mar; 33(1-2):319.
Score: 0.032
-
Blockade of the CD28/B7 and CD40/CD40L costimulatory pathways does not ameliorate chronic rejection in a mouse aortic allograft model of direct antigen presentation. Transplant Proc. 2001 Feb-Mar; 33(1-2):382.
Score: 0.032
-
Neutralization of IL-12 reverses rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with suppression of both cellular and humoral responses. Transplant Proc. 2001 Feb-Mar; 33(1-2):525.
Score: 0.032
-
Immune complex disease in immunosuppressed rat recipients of hamster liver xenografts. Transplant Proc. 2001 Feb-Mar; 33(1-2):778.
Score: 0.032
-
Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc. 2001 Feb-Mar; 33(1-2):1235-6.
Score: 0.032
-
Donor bone marrow infusion in liver recipients: effect on the occurrence of acute cellular rejection. Transplant Proc. 2001 Feb-Mar; 33(1-2):1352.
Score: 0.032
-
Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2 to 19 years follow-up. Transplant Proc. 2001 Feb-Mar; 33(1-2):1486-7.
Score: 0.032
-
Understanding and preventing late graft loss. Transplant Proc. 2000 Nov; 32(7):1514.
Score: 0.031
-
Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection. Immunology. 2000 Oct; 101(2):233-41.
Score: 0.031
-
The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transplant Proc. 2000 Sep; 32(6):1197-8.
Score: 0.031
-
Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000 Jun 15; 69(11):2330-6.
Score: 0.030
-
Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. Transplant Proc. 2000 May; 32(3):663-4.
Score: 0.030
-
Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc. 1999 Aug; 31(5):2028-31.
Score: 0.029
-
Renal transplantation in recipients over the age of 60: the impact of donor age. Transplantation. 1999 Apr 27; 67(8):1191-3.
Score: 0.028
-
Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg. 1999 Mar; 5(2):144-50.
Score: 0.028
-
Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms. Transplantation. 1999 Feb 15; 67(3):444-50.
Score: 0.028
-
Treatment with CTLA4-Ig inhibits rejection of liver allografts from FIt3-ligand-treated donors. Transplant Proc. 1999 Feb-Mar; 31(1-2):453.
Score: 0.028
-
Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. Transplant Proc. 1999 Feb-Mar; 31(1-2):700-1.
Score: 0.028
-
Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Transplant Proc. 1999 Feb-Mar; 31(1-2):1244.
Score: 0.028
-
A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol. 1998 Dec; 160(6 Pt 1):1982-5; discussion 1985-6.
Score: 0.027
-
A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation. 1998 Nov 27; 66(10):1395-8.
Score: 0.027
-
Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg. 1998 Nov; 4(6):448-54.
Score: 0.027
-
Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression. Ann Transplant. 2018 Oct 26; 23:751-757.
Score: 0.027
-
Combined blockade of CD28/B7 and CD40/CD40L costimulatory pathways prevents the onset of chronic rejection. Transplant Proc. 1998 Jun; 30(4):941-2.
Score: 0.026
-
Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc. 1998 Jun; 30(4):1257-60.
Score: 0.026
-
Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. Transplant Proc. 1998 Mar; 30(2):521.
Score: 0.026
-
Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation. 1997 Dec 27; 64(12):1838-43.
Score: 0.026
-
Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance. Transplantation. 1997 Sep 15; 64(5):690-5.
Score: 0.025
-
The immunolymphatic theory of chronic rejection. Transplant Proc. 1997 Sep; 29(6):2615-6.
Score: 0.025
-
Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc. 1997 Sep; 29(6):2737-8.
Score: 0.025
-
Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery. 2017 09; 162(3):525-536.
Score: 0.025
-
Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol. 1997 Feb; 150(2):563-78.
Score: 0.024
-
Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):306.
Score: 0.024
-
Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):310.
Score: 0.024
-
High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. Transplant Proc. 1997 Feb-Mar; 29(1-2):1081-2.
Score: 0.024
-
Apoptosis of graft-infiltrating cytotoxic T cells: a mechanism underlying "split tolerance" in mouse liver transplantation. Transplant Proc. 1997 Feb-Mar; 29(1-2):1168-9.
Score: 0.024
-
Enteric-drained pancreas transplants monitored by fine-needle aspiration biopsy. Transplant Proc. 1997 Feb-Mar; 29(1-2):674-5.
Score: 0.024
-
Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation. 1997 Jan 27; 63(2):223-8.
Score: 0.024
-
Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant. 1997; 2(2):27-44.
Score: 0.024
-
Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation. 1996 Dec 27; 62(12):1709-14.
Score: 0.024
-
"Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. Transplantation. 1996 Nov 15; 62(9):1242-6.
Score: 0.024
-
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg. 1996 Aug; 183(2):117-25.
Score: 0.023
-
Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc. 1996 Aug; 28(4):2119-20.
Score: 0.023
-
Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. Transplantation. 1996 Jun 27; 61(12):1730-5.
Score: 0.023
-
Daily serum interleukin-6 monitoring in multiple organ transplantation with or without liver allografts. Transplant Proc. 1996 Jun; 28(3):1229-34.
Score: 0.023
-
Daily serum inflammatory cytokine (tumor necrosis factor-alpha, interleukin-6) monitoring in liver transplantation focusing on allograft rejection: a five-case report. Transplant Proc. 1996 Jun; 28(3):1237-40.
Score: 0.023
-
Second-set rejection of mouse liver allografts is dependent on radiation-sensitive nonparenchymal cells of graft bone marrow origin. Transplantation. 1996 Apr 27; 61(8):1228-33.
Score: 0.023
-
The antigenicity of serum proteins and their role in xenograft rejection. Transplant Proc. 1996 Apr; 28(2):669-70.
Score: 0.023
-
Fine-needle aspiration biopsy in pancreatic transplantation. Transplant Proc. 1995 Dec; 27(6):3055-6.
Score: 0.022
-
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet. 1995 Nov 18; 346(8986):1346-50.
Score: 0.022
-
Rejection triggers liver transplant tolerance: Involvement of mesenchyme-mediated immune control mechanisms in mice. Hepatology. 2015 Sep; 62(3):915-31.
Score: 0.022
-
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation. 1995 Feb 27; 59(4):485-90.
Score: 0.021
-
Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. Transplant Proc. 1995 Feb; 27(1):277.
Score: 0.021
-
Mechanisms of protection from humoral rejection by a xenografted liver. Transplant Proc. 1995 Feb; 27(1):300-2.
Score: 0.021
-
The protection from humoral rejection given by a liver xenograft is species-specific and non-MHC restricted. Transplant Proc. 1995 Feb; 27(1):270.
Score: 0.021
-
The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us? Transplant Proc. 1995 Feb; 27(1):67-70.
Score: 0.021
-
The dichotomous functions of passenger leukocytes in solid-organ transplantation. Adv Nephrol Necker Hosp. 1995; 24:341-54.
Score: 0.021
-
FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. Transplant Proc. 1994 Jun; 26(3):1211.
Score: 0.020
-
Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. Transplant Proc. 1994 Jun; 26(3):1255.
Score: 0.020
-
Cytidine potentiates the inhibitory effect of brequinar sodium on concordant cardiac xenograft rejection. Transplant Proc. 1994 Jun; 26(3):1288-9.
Score: 0.020
-
Cotransplantation with myeloid-derived suppressor cells protects cell transplants: a crucial role of inducible nitric oxide synthase. Transplantation. 2014 Apr 15; 97(7):740-7.
Score: 0.020
-
Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells. Am J Pathol. 1993 Jul; 143(1):85-98.
Score: 0.019
-
Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. Transplant Proc. 1993 Jun; 25(3):2381-5.
Score: 0.019
-
Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol. 1993 May; 142(5):1383-91.
Score: 0.019
-
Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. Transplant Proc. 1993 Feb; 25(1 Pt 1):414-5.
Score: 0.018
-
Humoral rejection associated with antidonor lymphocytotoxic antibodies following liver transplantation. Transplant Proc. 1993 Feb; 25(1 Pt 2):888-90.
Score: 0.018
-
Intestinal transplantation in composite visceral grafts or alone. Ann Surg. 1992 Sep; 216(3):223-33; discussion 233-4.
Score: 0.018
-
A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology. 1992 Sep; 16(3):671-81.
Score: 0.018
-
Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation. 1992 May; 53(5):1056-62.
Score: 0.017
-
Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. Transplant Proc. 1991 Dec; 23(6):3023-5.
Score: 0.017
-
FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc. 1991 Dec; 23(6):3005-6.
Score: 0.017
-
[Clinical experience with FK 506]. Presse Med. 1991 Nov 27; 20(40):1967-73.
Score: 0.017
-
Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol. 1991 Mar; 138(3):609-18.
Score: 0.016
-
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc. 1991 Feb; 23(1 Pt 1):14-21.
Score: 0.016
-
Allogeneic orthotopic liver transplantation in mice: a preliminary study of rejection across well-defined MHC barriers. Transplant Proc. 1991 Feb; 23(1 Pt 1):705-6.
Score: 0.016
-
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery. 1990 Nov; 108(5):880-9.
Score: 0.016
-
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):25-34.
Score: 0.015
-
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc. 1990 Feb; 22(1):6-12.
Score: 0.015
-
Relationship between the diagnosis, preoperative evaluation, and prognosis after orthotopic liver transplantation. Ann Surg. 1988 Aug; 208(2):196-202.
Score: 0.013
-
OKT3 in the reversal of acute hepatic allograft rejection. Transplant Proc. 1987 Feb; 19(1 Pt 3):2443-6.
Score: 0.012
-
Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. Transplantation. 2006 Dec 27; 82(12):1649-52.
Score: 0.012
-
Caroli's disease and orthotopic liver transplantation. Liver Transpl. 2006 Mar; 12(3):416-21.
Score: 0.011
-
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006; 6(5 Pt 2):1111-31.
Score: 0.011
-
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl. 2005 Nov; 11(11):1343-52.
Score: 0.011
-
Lymphocytes of bronchoalveolar lavages from heart-lung transplant recipients. J Heart Transplant. 1985 Jul-Aug; 4(4):417-21.
Score: 0.011
-
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg. 2005 Apr; 200(4):505-15; quiz A59-61.
Score: 0.011
-
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation. 2004 Oct 15; 78(7):966-71.
Score: 0.010
-
Application of recipient-derived dendritic cells to induce donor-specific T-cell hyporesponsiveness. Transplant Proc. 2004 Jun; 36(5):1592-4.
Score: 0.010
-
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg. 2003 Oct; 238(4):520-5; discussion 525-7.
Score: 0.010
-
Prolonged survival of heart allografts transduced with AAV-CTLA4Ig. Microsurgery. 2003; 23(5):489-93.
Score: 0.009
-
Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance. J Immunol. 2001 May 01; 166(9):5619-28.
Score: 0.008
-
Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Transplant Proc. 2001 Feb-Mar; 33(1-2):129-30.
Score: 0.008
-
Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 2000 Sep 15; 70(5):760-4.
Score: 0.008
-
The long-term efficacy of multivisceral transplantation. Transplant Proc. 2000 Sep; 32(6):1219-20.
Score: 0.008
-
Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation. 2000 Jun 27; 69(12):2566-73.
Score: 0.008
-
A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg. 2000 Apr; 119(4 Pt 1):673-81.
Score: 0.008
-
Serum protein immunogenicity: implications for liver xenografting. Electrophoresis. 2000 Mar; 21(5):965-75.
Score: 0.007
-
Effects of donor bone marrow infusion in clinical lung transplantation. Ann Thorac Surg. 2000 Feb; 69(2):345-50.
Score: 0.007
-
Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation. 2000 Jan 27; 69(2):265-71.
Score: 0.007
-
Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999 Dec 27; 68(12):1851-4.
Score: 0.007
-
Differential effects of exogenous interleukin-10 on cardiac allograft survival: inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function. Transplantation. 1999 Nov 15; 68(9):1402-9.
Score: 0.007
-
An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1999 Sep 15; 68(5):650-5.
Score: 0.007
-
Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Ann Surg. 1999 Sep; 230(3):372-9; discussion 379-81.
Score: 0.007
-
Infusion of donor leukocytes to induce tolerance in organ allograft recipients. J Leukoc Biol. 1999 Aug; 66(2):310-4.
Score: 0.007
-
Marked mitigation of transplant vascular sclerosis in FasLgld (CD95L) mutant recipients. The role of alloantibodies in the development of chronic rejection. Transplantation. 1999 May 27; 67(10):1295-300.
Score: 0.007
-
Clinical intestinal transplantation in 1998: Pittsburgh experience. Acta Gastroenterol Belg. 1999 Apr-Jun; 62(2):244-7.
Score: 0.007
-
Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl Surg. 1999 Mar; 5(2):101-6.
Score: 0.007
-
Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. Transplant Proc. 1999 Feb-Mar; 31(1-2):646-7.
Score: 0.007
-
A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Transplant Proc. 1999 Feb-Mar; 31(1-2):1134.
Score: 0.007
-
Long-term results of pancreas transplantation under tacrolius immunosuppression. Transplantation. 1999 Jan 27; 67(2):266-72.
Score: 0.007
-
Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation. 1999 Jan 27; 67(2):299-303.
Score: 0.007
-
Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. Clin Transpl. 1999; 217-21.
Score: 0.007
-
Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1998 Oct 27; 66(8):1047-52.
Score: 0.007
-
Donor pretreatment with Flt-3 ligand augments antidonor cytotoxic T lymphocyte, natural killer, and lymphokine-activated killer cell activities within liver allografts and alters the pattern of intragraft apoptotic activity. Transplantation. 1998 Jun 27; 65(12):1590-8.
Score: 0.007
-
Adjuvant bone marrow infusion in clinical organ transplant recipients. Transplant Proc. 1998 Jun; 30(4):1367-8.
Score: 0.007
-
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg. 1998 May; 186(5):512-25; discussion 525-7.
Score: 0.007
-
Current status of intestinal transplantation in children. J Pediatr Surg. 1998 Feb; 33(2):243-54.
Score: 0.006
-
Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation. 1998 Jan 15; 65(1):82-6.
Score: 0.006
-
Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation. 1997 Dec 27; 64(12):1808-15.
Score: 0.006
-
Cardiac operations in solid-organ transplant recipients. Ann Thorac Surg. 1997 Nov; 64(5):1270-8.
Score: 0.006
-
Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients. Transplantation. 1997 Sep 15; 64(5):786-8.
Score: 0.006
-
Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997 Aug 27; 64(4):559-65.
Score: 0.006
-
Central venulitis in the allograft liver: a clinicopathologic study. Transplantation. 1997 Jul 27; 64(2):252-7.
Score: 0.006
-
Non-lymphoid cancer after liver transplantation. Hepatogastroenterology. 1997 Jul-Aug; 44(16):1172-81.
Score: 0.006
-
Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant Proc. 1997 Feb-Mar; 29(1-2):1174-7.
Score: 0.006
-
Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997 Jan 27; 63(2):243-9.
Score: 0.006
-
Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc. 1996 Oct; 28(5):2959-65.
Score: 0.006
-
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation. 1996 Sep 15; 62(5):659-65.
Score: 0.006
-
Use of MHC class I or II "knock out" mice to delineate the role of these molecules in acceptance/rejection of xenografts. Transplant Proc. 1996 Apr; 28(2):732.
Score: 0.006
-
Effect of donor age and sex on the outcome of liver transplantation. Hepatology. 1995 Dec; 22(6):1754-62.
Score: 0.006
-
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med. 1995 Aug 01; 182(2):379-87.
Score: 0.005
-
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation. 1995 Jul 27; 60(2):158-71.
Score: 0.005
-
Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology. 1995 May; 21(5):1345-52.
Score: 0.005
-
Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation. Transplant Proc. 1995 Apr; 27(2):1862-7.
Score: 0.005
-
A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc. 1995 Feb; 27(1):814-7.
Score: 0.005
-
Outcome of liver transplantation using donors 60 to 79 years of age. Transplant Proc. 1995 Feb; 27(1):1184-5.
Score: 0.005
-
Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol. 1995 Feb; 19(2):192-206.
Score: 0.005
-
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation. 1995 Jan 27; 59(2):212-7.
Score: 0.005
-
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology. 1994 Apr; 19(4):916-24.
Score: 0.005
-
Donor species complement after liver xenotransplantation. The mechanism of protection from hyperacute rejection. Transplantation. 1994 Mar 27; 57(6):918-22.
Score: 0.005
-
Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc. 1993 Feb; 25(1 Pt 1):669-72.
Score: 0.005
-
Intrahepatic human islet transplantation at the University of Pittsburgh: results in 25 consecutive cases. Transplant Proc. 1992 Dec; 24(6):3038-9.
Score: 0.005
-
Management of intestinal transplantation in humans. Transplant Proc. 1992 Jun; 24(3):1243-4.
Score: 0.004
-
Histologic monitoring of human small bowel allografts with clinical correlation. Transplant Proc. 1992 Jun; 24(3):1199-200.
Score: 0.004
-
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation. 1992 Feb; 53(2):369-76.
Score: 0.004
-
Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc. 1991 Dec; 23(6):2771-4.
Score: 0.004
-
FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc. 1991 Dec; 23(6):3010-5.
Score: 0.004
-
Clinical small bowel or small bowel plus liver transplantation under FK 506. Transplant Proc. 1991 Dec; 23(6):3093-5.
Score: 0.004
-
Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. Transplant Proc. 1991 Dec; 23(6):3148-9.
Score: 0.004
-
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg. 1990 Sep; 212(3):295-305; discussion 306-7.
Score: 0.004
-
Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol. 1990 Sep; 137(3):667-76.
Score: 0.004
-
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation. 1990 Aug; 50(2):186-9.
Score: 0.004
-
Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation. 1988 Sep; 46(3):372-7.
Score: 0.003
-
Immunological factors influencing liver graft survival. Gastroenterol Clin North Am. 1988 Mar; 17(1):53-9.
Score: 0.003
-
Effect of OKT3 on survival and rate of retransplantation. Transplant Proc. 1987 Aug; 19(4 Suppl 3):61-2.
Score: 0.003
-
Analysis of T lymphocytes infiltrating human hepatic allografts. Transplant Proc. 1987 Feb; 19(1 Pt 3):2470-3.
Score: 0.003
-
Sequential infiltration of class I and class II specific alloreactive T cells in human cardiac allografts. Transplant Proc. 1987 Feb; 19(1 Pt 3):2560-3.
Score: 0.003
-
Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants. Nephron. 1987; 46 Suppl 1:56-9.
Score: 0.003
-
The antibody crossmatch in liver transplantation. Surgery. 1986 Oct; 100(4):705-15.
Score: 0.003